Bioxcel therapeutics announces proposed public offering of common stock

New haven, conn., june 22, 2021 (globe newswire) -- bioxcel therapeutics, inc. (the “company”) (nasdaq: btai), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. in addition, a related party stockholder, bioxcel llc, expects to grant the underwriters a 30-day option to purchase up to $15.0 million of additional shares of common stock at the public offering price, less underwriting discounts and commissions.
BTAI Ratings Summary
BTAI Quant Ranking